These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31395514)

  • 41. Temporal trends of time to antiretroviral treatment initiation, interruption and modification: examination of patients diagnosed with advanced HIV in Australia.
    Wright ST; Law MG; Cooper DA; Keen P; McDonald A; Middleton M; Woolley I; Kelly M; Petoumenos K;
    J Int AIDS Soc; 2015; 18(1):19463. PubMed ID: 25865372
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report.
    Frange P; Faye A; Avettand-Fenoël V; Bellaton E; Descamps D; Angin M; David A; Caillat-Zucman S; Peytavin G; Dollfus C; Le Chenadec J; Warszawski J; Rouzioux C; Sáez-Cirión A;
    Lancet HIV; 2016 Jan; 3(1):e49-54. PubMed ID: 26762993
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.
    Goujard C; Girault I; Rouzioux C; Lécuroux C; Deveau C; Chaix ML; Jacomet C; Talamali A; Delfraissy JF; Venet A; Meyer L; Sinet M;
    Antivir Ther; 2012; 17(6):1001-9. PubMed ID: 22865544
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group.
    Neumann AU; Tubiana R; Calvez V; Robert C; Li TS; Agut H; Autran B; Katlama C
    AIDS; 1999 Apr; 13(6):677-83. PubMed ID: 10397562
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term health care interruptions among HIV-positive patients in Uganda.
    Mills EJ; Funk A; Kanters S; Kawuma E; Cooper C; Mukasa B; Odit M; Karamagi Y; Mwehire D; Nachega J; Yaya S; Featherstone A; Ford N
    J Acquir Immune Defic Syndr; 2013 May; 63(1):e23-7. PubMed ID: 23406979
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Growing challenges for HIV programmes in Asia: clinic population trends, 2003-2013.
    De La Mata NL; Kumarasamy N; Ly PS; Ng OT; Nguyen KV; Merati TP; Lee MP; Do CD; Choi JY; Ross JL; Law MG
    AIDS Care; 2017 Oct; 29(10):1243-1254. PubMed ID: 28132544
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A targeted approach for routine viral load monitoring in Malawian adults on antiretroviral therapy.
    Mungwira RG; Divala TH; Nyirenda OM; Kanjala M; Muwalo F; Mkandawire FA; Choko A; Taylor TE; Mallewa J; van Oosterhout JJ; Laufer MK; Laurens MB
    Trop Med Int Health; 2018 May; 23(5):526-532. PubMed ID: 29505108
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Relationship Between Time to Initiation of Antiretroviral Therapy and Treatment Outcomes: A Cohort Analysis of ART Eligible Adolescents in Zimbabwe.
    Vogt F; Rehman AM; Kranzer K; Nyathi M; Van Griensven J; Dixon M; Ndebele W; Gunguwo H; Colebunders R; Ndlovu M; Apollo T; Ferrand RA
    J Acquir Immune Defic Syndr; 2017 Apr; 74(4):390-398. PubMed ID: 28002183
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
    Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
    Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Trends in CD4 cell count response to first-line antiretroviral treatment in HIV-positive patients from Asia, 2003-2013: TREAT Asia HIV Observational Database Low Intensity Transfer.
    De La Mata NL; Ly PS; Ng OT; Nguyen KV; Merati TP; Pham TT; Lee MP; Choi JY; Sohn AH; Law MG; Kumarasamy N
    Int J STD AIDS; 2017 Nov; 28(13):1282-1291. PubMed ID: 28632481
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Improved survival in HIV treatment programmes in Asia.
    De La Mata NL; Kumarasamy N; Khol V; Ng OT; Van Nguyen K; Merati TP; Pham TT; Lee MP; Durier N; Law M
    Antivir Ther; 2016; 21(6):517-527. PubMed ID: 26961354
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term outcomes in adolescents perinatally infected with HIV-1 and followed up since birth in the French perinatal cohort (EPF/ANRS CO10).
    Dollfus C; Le Chenadec J; Faye A; Blanche S; Briand N; Rouzioux C; Warszawski J
    Clin Infect Dis; 2010 Jul; 51(2):214-24. PubMed ID: 20536367
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Treatment interruption in 30 HIV-infected patients with successful viral suppression under highly active antiretroviral treatment].
    Pavie J; Porcher R; Fournier S; André F; Tournoux C; Palmer P; Rabian C; Jean-Michel M
    Presse Med; 2005 Jun; 34(10 Suppl):1S8-13. PubMed ID: 16025661
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study).
    Castagna A; Muccini C; Galli L; Bigoloni A; Poli A; Spagnuolo V; Nozza S; Racca S; Galli A; Cinque P; Carini E; Lazzarin A
    J Antimicrob Chemother; 2019 Jul; 74(7):2039-2046. PubMed ID: 31225610
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Virological and immunological outcomes to antiretroviral therapy in HIV-infected patients of an academic medical center in Chile.
    Ceballos ME; Rojas Á; Donato P; Huilcamán M; Rivera G; López T; Gutiérrez C; Labarca J; Pérez C
    Rev Chilena Infectol; 2016 Oct; 33(5):531-536. PubMed ID: 28112336
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Virologic and immunologic failure, drug resistance and mortality during the first 24 months postpartum among HIV-infected women initiated on antiretroviral therapy for life in the Mitra plus Study, Dar es Salaam, Tanzania.
    Ngarina M; Kilewo C; Karlsson K; Aboud S; Karlsson A; Marrone G; Leyna G; Ekström AM; Biberfeld G
    BMC Infect Dis; 2015 Apr; 15():175. PubMed ID: 25886277
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.
    Mulu A; Maier M; Liebert UG
    PLoS One; 2015; 10(10):e0141318. PubMed ID: 26512902
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Persistence of genotypic resistance to nelfinavir among women exposed to prophylactic antiretroviral therapy during pregnancy.
    Kakehasi FM; Tupinambás U; Cleto S; Aleixo A; Lin E; Melo VH; Aguiar RA; Pinto JA
    AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1515-20. PubMed ID: 18160009
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chinese pediatric highly active antiretroviral therapy observational cohort: a 1-year analysis of clinical, immunologic, and virologic outcomes.
    Zhang F; Haberer JE; Zhao Y; Dou Z; Zhao H; He Y; Cao GH
    J Acquir Immune Defic Syndr; 2007 Dec; 46(5):594-8. PubMed ID: 18043313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.